Peptide and Anti-Aging Specialist Dr. Daniel Benhuri Now Offering Advanced Peptide Therapy, Including Semaglutide, in Beverly Hills and Los Angeles
Dr. Daniel Benhuri, a board-certified concierge physician in Beverly Hills, has introduced personalized peptide therapy to help patients optimize energy, metabolism, immunity, and recovery. The new service is available in-office or via concierge care throughout Beverly Hills and Los Angeles.
BEVERLY HILLS, Calif. , June 16, 2025 /PRNewswire/ -- Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now offering a full range of advanced peptide therapies designed to support weight loss, healing, hormone balance, sexual wellness, and cellular rejuvenation. Serving patients throughout Beverly Hills and the greater Los Angeles area, Dr. Benhuri's peptide programs now include widely requested options like Semaglutide, Tirzepatide, Tesamorelin, PT-141, BPC-157, and NAD+.
Peptides are short chains of amino acids that function as biological messengers, helping regulate metabolism, inflammation, recovery, and tissue repair. Dr. Benhuri's therapy protocols are fully customized based on labs, medical history, and patient goals—and are now available through in-office visits or concierge care across Los Angeles.
"Peptide therapy is a powerful tool that allows us to treat the root causes of fatigue, weight gain, inflammation, and low libido," said Dr. Benhuri. "These are evidence-based, well-tolerated therapies that fit perfectly into our concierge wellness model. Our patients want to optimize their lives, and peptides help us deliver exactly that."
Highlights of Dr. Benhuri's peptide therapy offerings include:
Semaglutide and Tirzepatide (GLP-1 agonists): Support sustainable weight loss by regulating appetite and improving insulin sensitivity.
Tesamorelin: Helps reduce visceral fat and promote lean muscle development.
PT-141: Enhances sexual desire and performance in both men and women.
BPC-157: Accelerates healing of soft tissue injuries and provides anti-inflammatory benefits.
NAD+ Therapy: Though not a peptide, NAD+ is a key coenzyme used for energy metabolism, anti-aging, and cognitive enhancement.
Dr. Benhuri's comprehensive programs begin with a detailed consultation and lab review. Based on individual needs, patients receive a personalized treatment plan that may include injectable peptides, nasal sprays, or topical solutions—all sourced from high-quality U.S. compounding pharmacies. Patients also benefit from ongoing clinical monitoring and adjustments as part of his concierge approach.
Known for his expertise in preventive care, weight management, and regenerative medicine, Dr. Benhuri offers these new services as a natural extension of his commitment to helping patients feel better, function better, and age with confidence.
More About Dr. Daniel Benhuri
Dr. Daniel Benhuri is a highly respected internal medicine and primary care physician serving patients in Beverly Hills and the surrounding areas. He offers a vast array of services, including advanced diagnostic imaging, executive physicals, medical weight loss plans, preventive care, and aesthetic treatments. By integrating concierge care and cutting-edge technology, Dr. Benhuri delivers an unmatched level of patient-focused care. His practice is located at 9400 Brighton Way, Suite 210, Beverly Hills, CA 90210. For more information or to schedule an appointment, visit www.danielbenhurimd.com or call (310) 362-1255.
Media ContactDr. Daniel Benhuri(310) 362-1255www.danielbenhurimd.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/peptide-and-anti-aging-specialist-dr-daniel-benhuri-now-offering-advanced-peptide-therapy-including-semaglutide-in-beverly-hills-and-los-angeles-302481967.html
SOURCE Daniel Benhuri M.D.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 minutes ago
- Associated Press
Nobel Biocare and 3Shape Announce Strategic Distribution Partnership
Nobel Biocare to Distribute 3Shape TRIOS® Intraoral Scanners ZURICH, June 23, 2025 /PRNewswire/ -- Nobel Biocare is pleased to announce a new distribution partnership with 3Shape, a global leader in 3D scanning and digital dental solutions. Through this collaboration, Nobel Biocare will become an official distributor of 3Shape's TRIOS® intraoral scanners, expanding its digital dentistry portfolio and delivering even greater value to dental professionals worldwide. 3Shape's TRIOS® scanners are widely recognized for their accuracy, ease of use, and patient-friendly scanning experience. This distribution agreement brings together 3Shape's innovative scanning technology with Nobel Biocare's trusted heritage in implant-based restorations and prosthetics, offering customers a streamlined digital workflow from scan to final restoration. At the same time, we would like to emphasize that the DEXIS IS scanner remains a core element of our offering — an enduring symbol of our strong and strategic partnership with DEXIS. This dual approach not only enhances the range of cutting-edge tools available to dental professionals but also reaffirms our pledge to quality care and innovation, instilling confidence among our customers and key stakeholders, including our valued Envista investors. 'At Nobel Biocare, our mission is to redefine what is possible in Dental care by empowering clinicians through innovation' said Rosemary O'Neill, VP/GM Procera and Digital Solutions 'By partnering with 3Shape and distributing TRIOS scanners, we're enabling our customers to access one of the most advanced intraoral scanning solutions available, supported by Nobel Biocare's expertise and service network.' Key benefits of the partnership include: 'We are excited to collaborate with Nobel Biocare to expand access to TRIOS,' said John Cusack, Chief Commercial Officer at 3Shape. 'This partnership ensures more dental professionals can benefit from a proven digital solution that enhances patient care and practice efficiency.' TRIOS scanners will be available in select markets for purchase through Nobel Biocare by end June 2025. For more information, please contact your local Nobel Biocare representative. About Nobel Biocare Nobel Biocare is a world leader in implant-based dental restorations. Our mission is to empower dental professionals to provide exceptional care through innovative solutions and clinical support. About 3Shape 3Shape is a global innovator in digital dentistry, empowering dental professionals to provide superior dental care for every patient, every time. Its award-winning digital solutions advance and connect practices and labs. Founded in Denmark in 2000, 3Shape employs more than 2,200 dedicated professionals, who together serve customers in 100+ countries. Private equity fund EQT has been a shareholder since 2022. For more information, visit Media contact: Lauren Meinhardt [email protected] View original content to download multimedia: SOURCE Nobel Biocare
Yahoo
11 hours ago
- Yahoo
Mounjaro weight loss jab: All you need to know
GPs in England will be able to prescribe weight loss jabs for the first time on the NHS on Monday, as the health service begins its mass rollout. Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
Yahoo
11 hours ago
- Yahoo
Mass rollout of weight loss jabs begins on NHS
The mass rollout of weight loss jabs on the NHS in England will begin on Monday as GPs are allowed to prescribe the drugs for the first time. Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years. The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. And pharmacy experts also said there could be pressure on supplies of the drug. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack. Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪 🔗Learn more: — EU Medicines Agency (@EMA_News) January 4, 2025 She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'. She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.' Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately. 'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly. 'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. 'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. 'The biggest concern we have is that prescribing these medications alone misses the point. 'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.' Around 29% of the adult population in the UK is obese. Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity. 'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay. 'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'
